<p>百时美施贵宝（NYSE:BMY - 获取免费报告）的股票在周三发布的报告中被 Guggenheim 的股票分析师重申了 “买入” 评级，Benzinga 报道。他们目前对这家生物制药公司的股票设定了 72.00 美元的目标价。Guggenheim 的目标价表明该股票当前价格有 24.82% 的潜在上涨空间。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>2 只值得增持的巴菲特股票——以及 1 只需要抛售的股票</li>
</ul>
<p>其他几位研究分析师也对该公司发表了评论。富国银行在 2 月 6 日的研究报告中重申了 “跑赢大盘” 评级，并将百时美施贵宝的目标价从 55.00 美元上调至 60.00 美元。Leerink Partners 在 1 月 13 日的研究报告中将百时美施贵宝的目标价从 54.00 美元上调至 60.00 美元，并给予该股票 “跑赢大盘” 评级。美国银行在 12 月 15 日的研究报告中将百时美施贵宝的评级从 “中性” 上调至 “买入”，并将其目标价从 52.00 美元上调至 61.00 美元。花旗集团在 2 月 6 日的研究报告中将百时美施贵宝的目标价从 60.00 美元上调至 64.00 美元，并给予该股票 “中性” 评级。最后，Piper Sandler 在 2 月 23 日的报告中重申了 “增持” 评级，并将百时美施贵宝的目标价从 66.00 美元上调至 75.00 美元。九位投资分析师对该股票给予了买入评级，十二位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 61.35 美元。</p>
<p><strong>获取我们关于百时美施贵宝的最新股票报告</strong></p>
<h2>百时美施贵宝的价格表现</h2>
<ul>
<li>为什么 GRAIL 股票可能成为生物技术领域的下一个重大突破</li>
</ul>
<p>周三，BMY 的股票开盘价为 57.68 美元。该公司的 50 日简单移动平均线为 59.51 美元，200 日简单移动平均线为 52.94 美元。该股票的市值为 1177.7 亿美元，市盈率为 16.72，市盈增长比率为 0.17，贝塔值为 0.27。百时美施贵宝的 1 年低点为 42.52 美元，1 年高点为 62.89 美元。该公司的债务与股本比率为 2.32，流动比率为 1.26，速动比率为 1.14。</p>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近一次发布季度财报是在 2 月 5 日。该生物制药公司报告本季度每股收益为 1.26 美元，低于分析师共识预期的 1.65 美元，差额为 0.39 美元。百时美施贵宝的股本回报率为 69.65%，净利润率为 14.64%。该公司本季度的收入为 125 亿美元，而分析师预期为 122.4 亿美元。在去年同期，该公司每股收益为 1.67 美元。该公司的季度收入同比增长 1.3%。百时美施贵宝已将其 2026 财年的指导目标设定为每股收益 6.050-6.350 美元。整体来看，分析师预测百时美施贵宝今年将发布每股收益 6.74 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>在相关消息中，执行副总裁 David V. Elkins 在 4 月 1 日的交易中出售了 30,000 股公司的股票。该股票以平均价格 61.67 美元出售，总价值为 1,850,100.00 美元。交易完成后，该执行副总裁直接持有公司股票 159,248 股，价值 9,820,824.16 美元。这代表其持股比例减少了 15.85%。该出售在向 SEC 提交的文件中披露，文件可通过此超链接获取。当前 0.09% 的股票由公司内部人士持有。</p>
<h2>对百时美施贵宝的对冲基金看法</h2>
<p>对冲基金最近对该公司的持仓进行了调整。J. Derek Lewis &amp; Associates Inc.在第四季度购买了百时美施贵宝的新股份，价值约 432,000 美元。Osbon Capital Management LLC 在第四季度获得了百时美施贵宝的新头寸，价值约 55,000 美元。World Investment Advisors 在第四季度将其在百时美施贵宝的持股增加了 14.1%。World Investment Advisors 目前持有该生物制药公司 64,471 股股票，价值 3,478,000 美元，在此期间又增持了 7,977 股。Nalls Sherbakoff Group LLC 在第四季度购买了百时美施贵宝的新头寸，价值约 92,000 美元。最后，Larry Mathis Financial Planning LLC 在第四季度获得了百时美施贵宝的新头寸，价值 427,000 美元。对冲基金和其他机构投资者持有该公司 76.41% 的股票。</p>
<h2>百时美施贵宝公司简介</h2>
<p>（获取免费报告）</p>
<p>百时美施贵宝是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。公司的核心业务包括研究与开发、临床开发、制造和商业化多个治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
<p>BMS 的市场产品组合和后期管线反映了对癌症和免疫介导疾病的强烈关注。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过百时美施贵宝</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

百时美施贵宝

<p>Guggenheim 重申了对百时美施贵宝（NYSE:BMY）的 “买入” 评级，目标价为 72.00 美元，意味着潜在上涨幅度为 24.82%。其他分析师也提高了他们的目标价，普遍评级为 “持有”，平均目标价为 61.35 美元。该股票开盘价为 57.68 美元，市值为 1177.7 亿美元。百时美施贵宝在上个季度报告的每股收益为 1.26 美元，低于预期，但收入为 125 亿美元，超出预期。公司对 2026 财年的指导为每股收益在 6.050-6.350 之间</p>

<p>Bristol Myers Squibb (NYSE:BMY - Get Free Report)'s stock had its &#34;buy&#34; rating reaffirmed by stock analysts at Guggenheim in a report released on Wednesday,Benzinga reports. They presently have a $72.00 price target on the biopharmaceutical company's stock. Guggenheim's target price indicates a potential upside of 24.82% from the stock's current price.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）的股票在周三发布的报告中被 Guggenheim 的股票分析师重申了 “买入” 评级，Benzinga 报道。他们目前对这家生物制药公司的股票设定了 72.00 美元的目标价。Guggenheim 的目标价表明该股票当前价格有 24.82% 的潜在上涨空间。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只值得增持的巴菲特股票——以及 1 只需要抛售的股票</li>
</ul>
</div><p>Several other research analysts have also commented on the company. Wells Fargo &amp; Company restated an &#34;outperform&#34; rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, January 13th. Bank of America raised Bristol Myers Squibb from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, February 6th. Finally, Piper Sandler reiterated an &#34;overweight&#34; rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $61.35.</p>
<div class="lb-trans"><p>其他几位研究分析师也对该公司发表了评论。富国银行在 2 月 6 日的研究报告中重申了 “跑赢大盘” 评级，并将百时美施贵宝的目标价从 55.00 美元上调至 60.00 美元。Leerink Partners 在 1 月 13 日的研究报告中将百时美施贵宝的目标价从 54.00 美元上调至 60.00 美元，并给予该股票 “跑赢大盘” 评级。美国银行在 12 月 15 日的研究报告中将百时美施贵宝的评级从 “中性” 上调至 “买入”，并将其目标价从 52.00 美元上调至 61.00 美元。花旗集团在 2 月 6 日的研究报告中将百时美施贵宝的目标价从 60.00 美元上调至 64.00 美元，并给予该股票 “中性” 评级。最后，Piper Sandler 在 2 月 23 日的报告中重申了 “增持” 评级，并将百时美施贵宝的目标价从 66.00 美元上调至 75.00 美元。九位投资分析师对该股票给予了买入评级，十二位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 61.35 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>获取我们关于百时美施贵宝的最新股票报告</strong></p>
</div><h2>Bristol Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝的价格表现</h2>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物技术领域的下一个重大突破</li>
</ul>
</div><p>Shares of BMY opened at $57.68 on Wednesday. The firm has a 50-day simple moving average of $59.51 and a two-hundred day simple moving average of $52.94. The stock has a market cap of $117.77 billion, a PE ratio of 16.72, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.</p>
<div class="lb-trans"><p>周三，BMY 的股票开盘价为 57.68 美元。该公司的 50 日简单移动平均线为 59.51 美元，200 日简单移动平均线为 52.94 美元。该股票的市值为 1177.7 亿美元，市盈率为 16.72，市盈增长比率为 0.17，贝塔值为 0.27。百时美施贵宝的 1 年低点为 42.52 美元，1 年高点为 62.89 美元。该公司的债务与股本比率为 2.32，流动比率为 1.26，速动比率为 1.14。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. During the same period in the previous year, the business posted $1.67 EPS. The business's revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近一次发布季度财报是在 2 月 5 日。该生物制药公司报告本季度每股收益为 1.26 美元，低于分析师共识预期的 1.65 美元，差额为 0.39 美元。百时美施贵宝的股本回报率为 69.65%，净利润率为 14.64%。该公司本季度的收入为 125 亿美元，而分析师预期为 122.4 亿美元。在去年同期，该公司每股收益为 1.67 美元。该公司的季度收入同比增长 1.3%。百时美施贵宝已将其 2026 财年的指导目标设定为每股收益 6.050-6.350 美元。整体来看，分析师预测百时美施贵宝今年将发布每股收益 6.74 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>In related news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 David V. Elkins 在 4 月 1 日的交易中出售了 30,000 股公司的股票。该股票以平均价格 61.67 美元出售，总价值为 1,850,100.00 美元。交易完成后，该执行副总裁直接持有公司股票 159,248 股，价值 9,820,824.16 美元。这代表其持股比例减少了 15.85%。该出售在向 SEC 提交的文件中披露，文件可通过此超链接获取。当前 0.09% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>对百时美施贵宝的对冲基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. J. Derek Lewis &amp; Associates Inc. purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $432,000. Osbon Capital Management LLC acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $55,000. World Investment Advisors boosted its holdings in shares of Bristol Myers Squibb by 14.1% in the fourth quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company's stock valued at $3,478,000 after acquiring an additional 7,977 shares during the period. Nalls Sherbakoff Group LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $92,000. Finally, Larry Mathis Financial Planning LLC acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $427,000. Hedge funds and other institutional investors own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。J. Derek Lewis &amp; Associates Inc.在第四季度购买了百时美施贵宝的新股份，价值约 432,000 美元。Osbon Capital Management LLC 在第四季度获得了百时美施贵宝的新头寸，价值约 55,000 美元。World Investment Advisors 在第四季度将其在百时美施贵宝的持股增加了 14.1%。World Investment Advisors 目前持有该生物制药公司 64,471 股股票，价值 3,478,000 美元，在此期间又增持了 7,977 股。Nalls Sherbakoff Group LLC 在第四季度购买了百时美施贵宝的新头寸，价值约 92,000 美元。最后，Larry Mathis Financial Planning LLC 在第四季度获得了百时美施贵宝的新头寸，价值 427,000 美元。对冲基金和其他机构投资者持有该公司 76.41% 的股票。</p>
</div><h2>Bristol Myers Squibb Company Profile</h2>
<div class="lb-trans"><h2>百时美施贵宝公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百时美施贵宝是一家全球生物制药公司，总部位于新泽西州普林斯顿，专注于发现、开发和提供针对严重疾病的药物。公司的核心业务包括研究与开发、临床开发、制造和商业化多个治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市场产品组合和后期管线反映了对癌症和免疫介导疾病的强烈关注。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过百时美施贵宝</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

百时美施贵宝公司（NYSE:BMY）获得古根海姆的买入评级